Avammune Therapeutics secures undisclosed funding from The Chennai Angels


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
The Chennai Angels have provided funding to Avammune Therapeutics Inc for the completion of IND enabling studies for their Immuno-oncology asset.

The funding will be used to advance Avammune's assets for cancer and autoimmune illnesses, according to the business.

"We are creating a revolutionary class of medications that harness the body's first line of defense against infections to attack cancer," says Dr. Aditya Kulkarni, Chief Scientific Officer of Avammune. These extremely powerful medications have the ability to overcome drug resistance and, due to their chemical composition, may be administered to patients as oral tablets, making them potentially more cheap alternatives to biological treatments."

Avammune is in active discussions with large pharmaceutical and biotech businesses about collaborating on clinical translation of the assets, as well as with strategic investors about bringing the assets through clinical testing independently.

Arun B Papaiah, CEO, Avammune said, “Avammune’s technology platform has been validated in various animal models and is gearing up for safety studies. With the influx of funding, we are hoping to complete these safety studies and are gearing up for partnerships for entering clinical testing next year. This latest round of funding will also allow us to further strengthen our diversified pipeline of drugs for cancers and autoimmune diseases. It is a pleasure working with The Chennai Angels who join existing and other new investors and are excited to bring them on board as partners.”

Avammune is in advanced talks with large pharmaceutical and biotech businesses about collaborating on clinical translation of the assets, as well as with strategic investors about bringing the assets through clinical testing independently.

According to Sameer Mehta, Director of Mehta's Multispecialty Hospital India Pvt Ltd and Lead Investor from The Chennai Angels, despite remarkable advances in the discovery and development of new cancer therapies, the illness continues to impact millions each year. TCA is excited to be a part of Avammune's Immuno-oncology asset development.

Tags : #fundingalert #avammune #investor #bussiness #studies #smitakumar #medicircle #funding

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026